General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Growth Stocks to Avoid Like the Plague: 3 Overpriced Picks Primed to Plummet | investorplace.com • |
Novavax Inc. stock underperforms Friday when compared to competitors | news.google.com • |
Why Novavax (NVAX) Stock Might be a Great Pick | news.google.com • |
Biotech Stock Roundup: GILD's Drug News, NVAX & MRNA COVID-19 Vaccine Updates | news.google.com • |
Here's How Much You Would Have Made Owning Novavax Stock In The Last 5 Years By Benzinga | news.google.com • |
Teacher Retirement System of Texas Sells 2984 Shares of Novavax, Inc. (NASDAQ:NVAX) | news.google.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-10 | 2024-03 | -1.04 | -1.05 | -0.01 | -0.96% |
2024-02-28 | 2023-12 | -0.49 | -1.44 | -0.95 | -193.88% |
2023-11-09 | 2023-09 | -1.82 | -1.26 | 0.56 | 30.77% |
2023-08-08 | 2023-06 | -1.24 | 0.58 | 1.82 | 146.77% |
2023-05-09 | 2023-03 | -3.38 | -3.41 | -0.03 | -0.89% |
2023-02-28 | 2022-12 | -0.92 | -2.28 | -1.36 | -147.83% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-08-09 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-08-08 | B. Riley Securities | Upgrade | Neutral | Buy |
2023-05-09 | HC Wainwright & Co. | Upgrade | Buy | |
2023-02-28 | B. Riley Securities | Downgrade | Buy | Neutral |
2023-02-12 | HC Wainwright & Co. | Upgrade | Buy | |
2023-01-01 | HC Wainwright & Co. | Upgrade | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-05-13 | DUBOVSKY FILIP | Officer | 38.95K | Sale |
2023-12-13 | HERRMANN JOHN A III | Officer | 13.23K | Conversion of Exercise of derivative security |
2024-01-22 | JACOBS JOHN C | Chief Executive Officer | 43.10K | Conversion of Exercise of derivative security |
2024-03-07 | KELLY JAMES PATRICK | Chief Financial Officer | 13.29K | Conversion of Exercise of derivative security |
2023-06-08 | MCGLYNN MARGARET G | Director | 3.80K | Conversion of Exercise of derivative security |
2023-06-08 | MOTT DAVID M | Director | 43.80K | Conversion of Exercise of derivative security |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | State Street Corporation | 11.68M | 86.78M | 12.37% |
2023-06-29 | Vanguard Group Inc | 10.57M | 78.55M | 11.20% |
2023-06-29 | Blackrock Inc. | 6.99M | 51.97M | 7.41% |
2023-09-29 | Shah Capital Management | 6.33M | 45.83M | 6.71% |
2023-06-29 | Bank of America Corporation | 2.18M | 16.23M | 2.31% |
2023-06-29 | Morgan Stanley | 2.08M | 15.46M | 2.20% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-08-30 | SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 9.38M | 75.07M | 9.94% |
2023-06-29 | Vanguard Total Stock Market Index Fund | 2.64M | 19.60M | 2.79% |
2023-06-29 | Vanguard Small-Cap Index Fund | 2.23M | 16.56M | 2.36% |
2023-08-30 | iShares Russell 2000 ETF | 2.01M | 16.10M | 2.13% |
2023-06-29 | Vanguard Small-Cap Growth Index Fund | 1.28M | 9.48M | 1.35% |
2023-06-29 | Vanguard Extended Market Index Fund | 1.21M | 8.98M | 1.28% |
Split | Date |
---|---|
1 : 20 | 2019-05-10 |
Only my opinion. I think NVAX has peaked. Already priced for perfection. Not much more upside. Remember that their previous work with the RSV vaccine failed. Went to cents and then they did a RS. This company is the equivalent to a paper tiger. Looks great on paper, but not so good in real life. Careful fellow investors.
Wall Street is always looking for the next big thing. Take some time and consider PDSB. Versamune technology is impressive. Animal studies show an exponential increase of Ab and more importantly T cells than conventional vaccines.
What’s up with this stock? Why is there no confidence here?
If you want the best vaccine candidate, look at PDSB. Significantly better Ab response and more importantly T cell levels than all the others. NVAX is significantly better than Moderna, but PDSB may top them all. It is behind in terms of timeline, but as we all know, it’s not about how you start, but how you finish.
Market Date Short Volume Total Volume Short Volume Ratio
2020-08-27 768,048 4,800,540 16.00%
What’s really going on behind the scenes?!
Good news! NVAX stock drops??????!!!!
Novavax Confirms Accelerated Approval Pathway Available for Licensure of NanoFlu
Novavax, Inc. recently announced it will utilize the accelerated approval pathway for licensure for NanoFlu, its nanoparticle seasonal influenza vaccine candidate. The US FDA acknowledged in a recent letter that the accelerated approval pathway is available to Novavax for its NanoFlu vaccine. Novavax expects to initiate its pivotal Phase 3 clinical trial by the fall of 2019 with top-line clinical data expected in the first quarter of 2020. These immunogenicity data are expected to support a US biologics license application (BLA).
Novavax will conduct an End-of-Phase 2 meeting with the FDA in the third quarter of 2019 to discuss the proposed Phase 3 clinical trial design and other topics that will support the future BLA. The accelerated approval pathway enables Novavax to conduct a non-inferiority immunogenicity clinical trial against a licensed quadrivalent comparator, with a commitment to confirm efficacy post-licensure.
“NanoFlu’s encouraging results observed in prior clinical trials, which demonstrated improved immune responses against licensed comparators, provide us confidence in the future success of the Phase 3 clinical trial,” said Gregory M. Glenn, MD, President of Research and Development of Novavax. “The accelerated approval pathway allows us to potentially obtain U.S. licensure more expeditiously, and ideally, deliver a greatly needed improved flu vaccine, which could reduce the tremendous medical and economic burden of influenza.”
“The accelerated approval pathway, combined with the strategic partnership we announced today with Catalent Biologics, allow us to efficiently and cost effectively complete the clinical development of NanoFlu through BLA and licensure,” said Stanley C. Erck, President and Chief Executive Officer of Novavax. “The Catalent deal provides an $18 million cash infusion and flexible manufacturing capacity, supported by the experienced professionals transferred from Novavax to Catalent.”
Watch what happens tomorrow
$120!!!!!
Patience now. Give it time
Look, this stock shot up so fast it has to come back down a little. It just makes sense. They are in phase 2 of trials, the government saw something in them to reward them with a $1.6 billion dollar grant to help ramp up production. Buy now, hold it with no fear and be glad you did in the end. I sold it right before it shot up to $110 from $50 I’m buying a crap load and holding. I’m confident in novavax they don’t just go to work every single day to let down the government or the American people. Research is also advancing to where, hey, we might actually be able to create vaccines in less than a year. New minds are coming together, the world is changing.
Did NVAX apply for BLA for nanoflu?
Stne launching now get in some contacts 52-55 ya